4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $49 | $77 | $134 | $149 |
| Short-Term Investments | $257 | $216 | $188 | $276 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $10 | $11 | $10 |
| Total Curr. Assets | $312 | $303 | $333 | $435 |
| Property Plant & Equip (Net) | $35 | $37 | $39 | $41 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $67 | $124 | $137 | $81 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $9 | $9 | $7 | $4 |
| Total NC Assets | $112 | $170 | $183 | $125 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $424 | $474 | $516 | $560 |
| Liabilities | – | – | – | – |
| Payables | $7 | $9 | $4 | $4 |
| Short-Term Debt | $6 | $6 | $6 | $6 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $1 | $1 | $0 |
| Other Curr. Liab. | $24 | $19 | $16 | $19 |
| Total Curr. Liab. | $37 | $35 | $27 | $29 |
| LT Debt | $17 | $17 | $18 | $19 |
| Deferred Rev, NC | $1 | $0 | $0 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $1 |
| Total NC Liab. | $18 | $18 | $19 | $21 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $22 | $23 | $24 | $25 |
| Total Liabilities | $55 | $53 | $46 | $50 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$736 | -$679 | -$624 | -$576 |
| AOCI | $1 | $0 | $0 | $0 |
| Other Equity | $1,104 | $1,099 | $1,094 | $1,087 |
| Total Equity | $369 | $421 | $470 | $511 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $424 | $474 | $516 | $560 |
| Net Debt | -$26 | -$54 | -$110 | -$125 |